TY - JOUR
T1 - Chemotherapy-induced nausea and vomiting in patients with breast cancer
T2 - a prospective cohort study
AU - Naito, Yoichi
AU - Kai, Yuichiro
AU - Ishikawa, Takashi
AU - Fujita, Tomoyuki
AU - Uehara, Kanou
AU - Doihara, Hiroyoshi
AU - Tokunaga, Shinya
AU - Shimokawa, Mototsugu
AU - Ito, Yoshinori
AU - Saeki, Toshiaki
N1 - Funding Information:
Toshiaki Saeki has received speaker honorarium from Novartis and financial support for educational programs from Taiho Pharmaceutical Co., Ltd. and Eisai Co., Ltd. Yoichi Naito, Yuichiro Kai, Takashi Ishikawa, Tomoyuki Fujita, Kanou Uehara, Hiroyoshi Doihara, Shinya Tokunaga, Mototsugu Shimokawa, and Yoshinori Ito have declared no conflict of interest.
Funding Information:
The authors received a research grant from the Public Health Research Foundation.
Funding Information:
The authors thank Etsuko Kumakawa, Yukimi Itoh, Noriko Ikoma, Noriko Gushima, and Kazuko Nakata for assisting with the registration and analysis of the collected data. We are grateful to Kazuo Tamura and Keisuke Aiba for their helpful advice as members of the Scientific Committee, and Masaki Kitajima, Yoshihiko Maehara, and Koichi Hirata as members of the Executive Council. The authors also thank all patients and investigators who participated in this study.
Publisher Copyright:
© 2019, The Author(s).
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Purpose: To explore the actual status of chemotherapy-induced nausea and vomiting (CINV) through a multicenter prospective cohort study. Methods: Patients with breast cancer treated with moderately emetogenic (MEC) or highly emetogenic (HEC) chemotherapy were eligible. A 7-day diary was provided for all patients. Acute and delayed CINV were defined as nausea and vomiting that developed ≤ 24 or > 24 h after the start of chemotherapy, respectively. The severity of nausea was evaluated with a visual analog scale (VAS). We also assessed the accuracy of estimations of CINV by medical staff. Results: In total, 426 patients were included; 352 patients (82.6%) received HEC, and 74 (17.3%) received MEC. In the acute phase, 44.9% of patients receiving HEC and 5.4% receiving MEC experienced nausea, and 12.8% receiving HEC and none receiving MEC experienced vomiting. More patients experienced nausea in both groups and vomiting in MEC during the delayed phase (nausea: 59.4% in HEC and 44.6% in MEC group; vomiting: 11.1% in HEC; and 13.5% in MEC group) than during the acute phase. Estimations of CINV by medical staff were not accurate, with a kappa coefficient of 0.10 and 0.08 for acute nausea and vomiting and 0.02 and 0.01 for delayed. The VAS scores showed that in the HEC group, the degree of nausea was worst on the first day. Conclusions: The degree of nausea was worst in the acute phase, although delayed nausea was more in proportion in HEC. Estimation by medical staff is not accurate.
AB - Purpose: To explore the actual status of chemotherapy-induced nausea and vomiting (CINV) through a multicenter prospective cohort study. Methods: Patients with breast cancer treated with moderately emetogenic (MEC) or highly emetogenic (HEC) chemotherapy were eligible. A 7-day diary was provided for all patients. Acute and delayed CINV were defined as nausea and vomiting that developed ≤ 24 or > 24 h after the start of chemotherapy, respectively. The severity of nausea was evaluated with a visual analog scale (VAS). We also assessed the accuracy of estimations of CINV by medical staff. Results: In total, 426 patients were included; 352 patients (82.6%) received HEC, and 74 (17.3%) received MEC. In the acute phase, 44.9% of patients receiving HEC and 5.4% receiving MEC experienced nausea, and 12.8% receiving HEC and none receiving MEC experienced vomiting. More patients experienced nausea in both groups and vomiting in MEC during the delayed phase (nausea: 59.4% in HEC and 44.6% in MEC group; vomiting: 11.1% in HEC; and 13.5% in MEC group) than during the acute phase. Estimations of CINV by medical staff were not accurate, with a kappa coefficient of 0.10 and 0.08 for acute nausea and vomiting and 0.02 and 0.01 for delayed. The VAS scores showed that in the HEC group, the degree of nausea was worst on the first day. Conclusions: The degree of nausea was worst in the acute phase, although delayed nausea was more in proportion in HEC. Estimation by medical staff is not accurate.
KW - Antiemetics
KW - Breast cancer
KW - Chemotherapy-induced nausea and vomiting
KW - Guideline
UR - http://www.scopus.com/inward/record.url?scp=85070783593&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070783593&partnerID=8YFLogxK
U2 - 10.1007/s12282-019-01001-1
DO - 10.1007/s12282-019-01001-1
M3 - Article
C2 - 31407150
AN - SCOPUS:85070783593
SN - 1340-6868
VL - 27
SP - 122
EP - 128
JO - Breast Cancer
JF - Breast Cancer
IS - 1
ER -
